Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of CT-707 in crizotinib-resistant advanced ALK-positive non-small cell lung cancer
CTR20181770Phase 2Completed
- Sponsor
- Beijing Sailintai Pharmaceutical Technology
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of conteltinib in non-small cell lung cancer (NSCLC), sponsored by Beijing Sailintai Pharmaceutical Technology. Started Sep 2019; status: completed.
02
Drugs
conteltinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20181770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181770.